landing page COVID-19 tests

COVID-19 tests overview

In a nutshell: reliable tests detecting COVID-19

Tests rapides: résultat disponible en 15 minutes
Tests rapides: résultat disponible en 15 minutes

Rapid Point of Care SARS-CoV-2 assays

Roche Diagnostics offers two rapid tests for point of care: Rapid Antigen Tests and Antibody tests

 

Rapid Antigen Tests

The SARS-CoV-2 Rapid Antigen Tests are for use in point of care settings and are offered in different forms depending on the sampling. The test can help healthcare professionals or individuals to identify a SARS-CoV-2 infection in people suspected to carry the virus with results typically ready in 15 minutes. We offer the following tests: 

For patients:

  • Roche SARS-CoV-2 Rapid Antigen Self Test Nasal for self testing
For healthcare professionals:
 

 

Rapid Antibody Test

The SARS-CoV-2 Rapid Antibody Test is a reliable, rapid chromatographic immunoassay intended for qualitative detection of antibodies (IgM and IgG) to SARS-CoV-2 in human serum, plasma or whole blood.

Roche molecular tests

Molecular SARS-CoV-2 Assays (including Molecular point of Care)

Molecular tests use Real Time -PCR for the qualitative detection of SARS-CoV-2 or in combination with Influenza in nasopharyngeal and oropharyngeal swab samples from patients.

 

Molecular assays:

cobas® SARS-CoV-2 Test

cobas® SARS-CoV-2 & Influenza A/B Test

 
Molecular point of care assays:

cobas® Liat® SARS-CoV-2 Test

cobas® Liat SARS-CoV-2 & Influenza A/B Test

Diagnostic et dépistage en laboratoire

High throughput assays

HIGH THROUHGPUT ANTIBODY AND ANTIGEN SARS-COV-2 ASSAYS

The Elecsys® Anti-SARS-CoV-2 Antibody Tests are immunoassay for the in vitro qualitative detection of antibodies (including IgG) to SARS-CoV-2 in human serum and plasma. The test is intended as an aid in the determination of the immune reaction to SARS-CoV-2 (important: tests should be performed by medical or laboratory personnel).

The Elecsys® SARS-CoV-2 Antigen test could be used as an alternative or in conjunction with PCR testing. In symptomatic individuals, a positive result with the Elecsys®  SARS-CoV-2 Antigen test indicates an active SARS-CoV-2 infection with a likelihood of 94.5%.

Elecsys® Anti-SARS-CoV-2 Test

Elecsys® Anti-SARS-CoV-2 S Test

Elecsys® SARS-CoV-2 Antigen Test

Digital solutions from Roche to support COVID-19 testing

cobas® infinity POC COVID-19 Portal

The cobas® infinity POC COVID-19 Portal allows easy digitization of the Roche® SARS CoV-2-Rapid Ag & Ab test results. Using existing infrastructure in terms of cobas® Infinity POC and cobas® IT 1000, the analogue test result is being digitized, ensuring that all patient data moves from the portal to the cobas middleware to the LIS, before finally residing in the customer& EMR.

Diagnostic et dépistage en laboratoire

Would you like to know more or ask a demo of cobas® infinity POC COVID-19 Portal?

Get in touch with us!

Diagnostic et dépistage en laboratoire

NAVIFY®  Pass Solution

The NAVIFY® Pass solution is a test agnostic platform intended for health care professionals and test recipients. NAVIFY®  Pass allows test recipients to register a personal profile, and use this as a means of authentication when accessing a test site that is using NAVIFY® Pass Professional.

A testing entity can quickly and easily configure their testing operation in NAVIFY® Pass Professional, enabling multiple operators to deliver the same digital workflow, performing and recording COVID-19 tests.

Easy and quick installation of NAVIFY Pass

Self Testing with NAVIFY Pass

Watch the step by step guide on how NAVIFY Pass helps you unlocking the digital potential of your SARS-CoV-2 Antigent Self Test.

NAVIFY Pass Workflow

Learn how the NAVIFY Pass workflow comes to life.

Download the app now

NAVIFY Pass can be downloaded from both the Apple App Store and Google Play.

 

Download from Apple App Store

Download from Google Play

App Store Logo
Play Store Logo

Our contribution in the fight against COVID-19 pandemic

The emergence of SARS-Cov-2, including the virus that caused Covid-19, has raised many questions about how to deal with the virus. Many of these questions are answered with the help of diagnostic tests. Roche has acquired a comprehensive portfolio for Covid-19 screening.

Roche and the COVID-19 pandemic

Notre contribution à la lutte contre la pandémie de COVID-19